Evoke Pharma, Inc. – NASDAQ:EVOK
Evoke Pharma stock price today
Evoke Pharma stock price monthly change
Evoke Pharma stock price quarterly change
Evoke Pharma stock price yearly change
Evoke Pharma key metrics
Market Cap | 7.35M |
Enterprise value | N/A |
P/E | -0.67 |
EV/Sales | -1.45 |
EV/EBITDA | 0.47 |
Price/Sales | 2.41 |
Price/Book | 1.48 |
PEG ratio | -0.03 |
EPS | -1.83 |
Revenue | 6.10M |
EBITDA | -6.70M |
Income | -7.12M |
Revenue Q/Q | 114.15% |
Revenue Y/Y | 110.49% |
Profit margin | -327.83% |
Oper. margin | -310.37% |
Gross margin | 85.24% |
EBIT margin | -310.37% |
EBITDA margin | -109.74% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEvoke Pharma stock price history
Evoke Pharma stock forecast
Evoke Pharma financial statements
$18
Potential upside: 214.68%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1.13M | -1.86M | -165.1% |
|---|---|---|---|
| Sep 2023 | 1.56M | -1.69M | -108.39% |
| Dec 2023 | 1.67M | -1.98M | -118.58% |
| Mar 2024 | 1.73M | -1.57M | -91.03% |
| Jun 2023 | 8979697 | 8.44M | 94% |
|---|---|---|---|
| Sep 2023 | 7852974 | 8.72M | 111.13% |
| Dec 2023 | 7068546 | 9.64M | 136.49% |
| Mar 2024 | 12453962 | 8.95M | 71.92% |
| Jun 2023 | -1.20M | 0 | 0 |
|---|---|---|---|
| Sep 2023 | -1.04M | 0 | 0 |
| Dec 2023 | -1.10M | 0 | -119.29K |
| Mar 2024 | -2.57M | 0 | 7.54M |
Evoke Pharma alternative data
| Aug 2023 | 4 |
|---|---|
| Sep 2023 | 4 |
| Oct 2023 | 4 |
| Nov 2023 | 4 |
| Dec 2023 | 4 |
| Jan 2024 | 4 |
| Feb 2024 | 4 |
| Mar 2024 | 4 |
| Apr 2024 | 4 |
| May 2024 | 4 |
| Jun 2024 | 4 |
| Jul 2024 | 4 |
Evoke Pharma other data
| Period | Buy | Sel |
|---|---|---|
| Dec 2020 | 0 | 118000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | GONYER DAVID A director, officer.. | Common Stock | 23,954 | $2.94 | $70,425 | ||
Sale | D'ONOFRIO MATTHEW J officer: Exec VP,.. | Common Stock | 40,357 | $2.91 | $117,439 | ||
Sale | GONYER DAVID A director, officer.. | Common Stock | 48,046 | $2.9 | $139,333 | ||
Sale | D'ONOFRIO MATTHEW J officer: Exec VP,.. | Common Stock | 5,643 | $2.95 | $16,647 | ||
Option | GONYER DAVID A director, officer.. | Stock Option (Right to Buy) | 72,000 | $0.4 | $28,800 | ||
Option | GONYER DAVID A director, officer.. | Common Stock | 72,000 | $0.4 | $28,800 | ||
Option | D'ONOFRIO MATTHEW J officer: Exec VP,.. | Common Stock | 46,000 | $0.4 | $18,400 | ||
Option | D'ONOFRIO MATTHEW J officer: Exec VP,.. | Stock Option (Right to Buy) | 46,000 | $0.4 | $18,400 | ||
Purchase | LVP GP III, LLC 10 percent owner | Common Stock | 500,000 | $2.35 | $1,175,000 | ||
Purchase | LVP GP III, LLC 10 percent owner | Common Stock | 500,000 | $2.35 | $1,175,000 |
| Patent |
|---|
Application Filling date: 21 Jul 2021 Issue date: 19 May 2022 |
Application Filling date: 2 Jul 2021 Issue date: 4 Nov 2021 |
Application Filling date: 2 Jul 2021 Issue date: 28 Oct 2021 |
Application Filling date: 2 Jul 2021 Issue date: 28 Oct 2021 |
Application Filling date: 20 Nov 2020 Issue date: 1 Apr 2021 |
Application Filling date: 22 Jun 2018 Issue date: 31 Dec 2020 |
Application Filling date: 10 Sep 2018 Issue date: 3 Sep 2020 |
Application Filling date: 22 Jun 2018 Issue date: 26 Dec 2019 |
Application Filling date: 13 Dec 2017 Issue date: 31 Oct 2019 |
| Quarter | Transcript |
|---|---|
| Q4 2023 14 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q4 2022 21 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 9 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 10 Aug 2022 | Q2 2022 Earnings Call Transcript |
-
What's the price of Evoke Pharma stock today?
One share of Evoke Pharma stock can currently be purchased for approximately $5.72.
-
When is Evoke Pharma's next earnings date?
Unfortunately, Evoke Pharma's (EVOK) next earnings date is currently unknown.
-
Does Evoke Pharma pay dividends?
No, Evoke Pharma does not pay dividends.
-
How much money does Evoke Pharma make?
Evoke Pharma has a market capitalization of 7.35M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 106.51% to 5.18M US dollars.
-
What is Evoke Pharma's stock symbol?
Evoke Pharma, Inc. is traded on the NASDAQ under the ticker symbol "EVOK".
-
What is Evoke Pharma's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Evoke Pharma?
Shares of Evoke Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Evoke Pharma's key executives?
Evoke Pharma's management team includes the following people:
- Mr. David A. Gonyer Co-Founder, Chief Executive Officer, Pres & Director(age: 61, pay: $857,330)
- Mr. Matthew J. D'Onofrio Co-Founder, Chief Bus. Officer, Executive Vice President, Treasurer & Sec.(age: 55, pay: $634,640)
- Dr. Marilyn R. Carlson Chief Medical Officer(age: 77, pay: $569,660)
-
Is Evoke Pharma founder-led company?
Yes, Evoke Pharma is a company led by its founders Mr. David A. Gonyer and Mr. Matthew J. D'Onofrio.
-
How many employees does Evoke Pharma have?
As Jul 2024, Evoke Pharma employs 4 workers.
-
When Evoke Pharma went public?
Evoke Pharma, Inc. is publicly traded company for more then 11 years since IPO on 25 Sep 2013.
-
What is Evoke Pharma's official website?
The official website for Evoke Pharma is evokepharma.com.
-
Where are Evoke Pharma's headquarters?
Evoke Pharma is headquartered at 420 Stevens Avenue, Solana Beach, CA.
-
How can i contact Evoke Pharma?
Evoke Pharma's mailing address is 420 Stevens Avenue, Solana Beach, CA and company can be reached via phone at 858 345 1494.
-
What is Evoke Pharma stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Evoke Pharma in the last 12 months, the avarage price target is $18. The average price target represents a 214.68% change from the last price of $5.72.
Evoke Pharma company profile:
Evoke Pharma, Inc.
evokepharma.comNASDAQ
4
Drug Manufacturers - Specialty & Generic
Healthcare
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Solana Beach, CA 92075
CIK: 0001403708
ISIN: US30049G2030
CUSIP: 30049G104
